« News

Helsinn Group to present at ASCO pooled follow up efficacy data analysis from two Phase III studies for anamorelin in cachectic patients with non-small cell lung cancer (NSCLC)

Helsinn Healthcare SA

Pooled, post-hoc efficacy data analysis from the ROMANA 1 and ROMANA 2 Phase III studies
demonstrates that in NSCLC patients with cachexia and a low BMI, anamorelin significantly
improves fatigue in addition to symptom burden (including appetite) and increases lean body
mass and fat

2016-06-01– Anamorelin ASCO FINAL